If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Pacira BioSciences, Inc. (NASDAQ: PCRX ) stock currently trades at a value of $18, although in 2015 it traded at $115 per share, and in March 2022, >$75 per share. Since th ...

Pacira BioSciences, Inc. (PCRX) reported third-quarter 2024 adjusted earnings of 79 cents per share, which beat the Zacks Consensus Estimate of 72 cents. The company had reported adjusted earnings of 72 cents per share in the year-ago quarter.Total revenues amounted to $168.6 million, which increased 3% year over year but missed the Zacks Consensus Estimate of $169 million.PCRX’s Q3 Results in DetailPacira’s top line comprises product sales and royalty revenues. The company recognizes product revenues from ...

Pacira Biosciences Inc. (NASDAQ:PCRX) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Shawn Cross - Chief Financial Officer Kristen Williams - Chief Administrative Officer Lauren Riker - Senior Vice President Finance Jonathan Slonin - Chief Medical Officer Conference Call Participants Oren Livnat - H.C. Wainwright David Amsellem - Piper Sandler Les Sulewski - Truist Securities Operator Good day, an ...

Pacira (PCRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.72%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.73 per share when it actually produced earnings of $0.89, delivering a surprise of 21.92%.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (State or Other J ...

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Third Quarter 2024 Financial Results -- Conference call today at 4:30 p.m. ET -- PARSIPPANY, NJ, November 6, 2024 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today reported financial results for the third quarter of 2024. Third Quarter 2024 Financial Highlights • Total revenues of $168.6 million • Net product sales of $132.0 million for EXPAREL, $28.4 million for ZILRETT ...

PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing the ...

Pacira BioSciences (PCRX) announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code (J0666) for its lead pain-management drug, Exparel (bupivacaine liposome injectable suspension), to facilitate better insurance coverage for the drug. This new J-code will take effect on Jan. 1, 2025, replacing the existing C-code (C9290), which has been in use since 2019. Please note that J-codes are reimbursement codes used by insurance companies, including Medicare ...

-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for EXPAREL® (bupivacaine lipos ...

Core Viewpoint - Pacira BioSciences' shares dropped 47.7% following a court ruling that invalidated its '495 patent for Exparel, which could lead to generic competition and significantly impact the company's revenue potential [1]. Company Overview - Pacira's flagship product, Exparel, is a long-acting local analgesic launched in 2012, approved for various postsurgical pain management applications [2]. - In the second quarter of 2024, Exparel generated $137 million in net sales, accounting for 77% of Pacira's total revenues for that quarter [6]. Legal Context - The court ruling is part of ongoing litigation against eVenus Pharmaceutical Laboratories, which aims to launch a generic version of Exparel [3]. - eVenus has countered Pacira's lawsuit by claiming the '495 patent is invalid and/or not infringed [4]. Financial Impact - The invalidation of the patent poses a significant risk to Pacira's revenue, as Exparel's sales are crucial for the company's financial health, and other products like Zilretta and iovera have not yet gained significant market traction [6][7]. - Year-to-date, Pacira's shares have declined 65.3%, contrasting with a 3.4% decline in the industry [6]. Future Considerations - Pacira is exploring legal options, including an appellate review at the U.S. Court of Appeals for the Federal Court [7]. - The company asserts that its Exparel franchise is protected by multiple existing patents, with additional infringement suits and patents in progress [8].